Global investment in R&D for PrEP contracted by 40 percent in 2015, down to US$29 million from US$48 million in 2014. This decline was driven by a steep drop in funding from the philanthropic sector, most notably the BMGF that decreased its investments to this area by almost 90 percent. The commercial sector, conversely, increased its contribution by 60 percent over 2014 levels thanks to Gilead’s long-term investment into implementation and demonstration projects through PEPFAR’s DREAMS initiative.
Fully 53 percent of allocations to PrEP R&D went to these implementation and demonstration projects, and the projects themselves spanned the globe and sought to target a wide variety of populations. Other news in the PrEP-sphere in 2015 included the decision by the WHO to expand its recommendation on PrEP to include all populations at substantial risk of HIV. It is hoped that in future years this will inspire more rather than less funding, as seen in current trends, toward this very effective arena of HIV prevention.